[Source](https://github.com/mm80843/T3.5/blob/main/docs/index.md) -- [RiskMitigation](https://github.com/mm80843/T3.5/tree/main/docs/RiskMitigation/index.md) 

# RiskMitigation: __Evaluation of symptoms__ (PBN__Mitigation_1626)

## Property: has_MitigationRisk

* [Symptomatic vs asymptomatic](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_3176.md)

## Property: has_MitigationSource

* [pilz_contributions_2022](https://github.com/mm80843/T3.5/blob/main/docs/Article/PBN__Article_245.md)

## Property: has_MitigationTechnology

* [clinical assessment](https://github.com/mm80843/T3.5/blob/main/docs/Technology/PBN__Technology_3957.md)

## Property: has_MitigationPrinciple

Assesses whether the efficacy of protection against re-infections differs in individuals with and without symptoms during their first infection

